Published October 8, 2021 | Version v1

Interaction of nanoparticles with lipid films: the role of symmetry and shape anisotropy

Description

The bioactivity, biological fate and cytotoxicity of nanomaterials when they come into contact with living organisms are determined by their interaction with biomacromolecules and biological barriers. In this context, the role of symmetry/shape anisotropy of both the nanomaterials and biological interfaces in their mutual interaction, is a relatively unaddressed issue. Here, we study the interaction of gold nanoparticles (NPs) of different shapes (nanospheres and nanorods) with biomimetic membranes of different morphology, i.e. flat membranes (2D symmetry, representative of the most common plasma membrane geometry), and cubic membranes (3D symmetry, representative of non-lamellar membranes, found in Nature under certain biological conditions). For this purpose we used an ensemble of complementary structural techniques, including Neutron Reflectometry, Grazing Incidence Small-Angle Neutron Scattering, on a nanometer lengthscale and Confocal Laser Scanning Microscopy on a micrometer length scale. We found that the structural stability of the membrane towards NPs is dependent on the topological characteristic of the lipid assembly and of the NPs, where a higher symmetry gave higher stability. In addition, Confocal Laser Scanning Microscopy analyses highlighted that NPs interact with cubic and lamellar phases according to two distinct mechanisms, related to the different structures of the lipid assemblies. This study for the first time systematically addresses the role of NPs shape in the interaction with lipid assemblies with different symmetry. The results will contribute to improve the fundamental knowledge on lipid interfaces and will provide new insights on the biological function of phase transitions as a response strategy to the exposure of NPs.

Files

1.png

Files (1.4 MB)

Name Size Download all
md5:2de0c9bcea34ffd17dc7a750ca1715b8
81.1 kB Preview Download
md5:ac49b2046326acdccf4e2f5834e63d7b
84.1 kB Preview Download
md5:5a1d0a227e728d71743ba6de9742a421
79.2 kB Preview Download
md5:d906832d4beb09e825c653767380f174
87.8 kB Preview Download
md5:ebb68adc4193fb12f9f9479709842721
82.2 kB Preview Download
md5:1e31a837753b93adf247ed8f43ad4309
85.4 kB Preview Download
md5:8b59e9f1a0718b1246a00c3495f41b21
274.1 kB Preview Download
md5:5af7a8331ab7a5ecac45494ec88e61ee
254.0 kB Preview Download
md5:93fcd868ff0bdaab45b2249cfd673521
67.7 kB Preview Download
md5:702fbc43bfc7239fac23a22958fb398b
143.2 kB Preview Download
md5:872293ed5da6eb3c6053b9b50f5c1f82
104.4 kB Preview Download
md5:d94d2be14bc4d573cdd465ea1d8b5de3
81.1 kB Preview Download

Additional details

Funding

European Commission
evFOUNDRY - The Extracellular Vesicle Foundry 801367